Resumo

CESPEDES QUEVEDO, María Cristina et al. Granulocyte-colony stimulating factor in patients with cancer. MEDISAN [online]. 2013, vol.17, n.1, pp. 45-53. ISSN 1029-3019.

A descriptive, longitudinal and prospective study was conducted in 26 patients with cancer in different locations associated with leukopenia and neutropenia induced by cytotoxic drugs, treated at the Chemotherapy Department of "Conrado Benítez" Teaching Oncology Hospital of Santiago de Cuba, from May 2011 to the same month of 2012, with the purpose of determining the effect of the recombinant granulocyte-colony factor Ior® LeukoCIM --produced by the Center of Molecular Immunology in Havana city-- in them by means of global counts of leukocytes and neutrophils before and after applying the treatment. Female sex, breast cancer and clinical stage II prevailed in the series. It was also found that 92.3% of patients responded successfully to the therapy, the clinical stage of cancer did not modify the myelosuppressive effect of cytotoxic drugs nor the myelostimulating effect of hormone, and cisplatin and adriamycin were related to higher neutropenia and lack of reaction to the factor. Finally, the Ior® LeukoCIM stimulated the granulopoietic system of most patients.

Palavras-chave : cancer; granulocyte-colony stimulating factor; leukopenia; neutropenia; Ior^® LeukoCIM; Chemotherapy Department.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )